Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm rVA576 study in mild to moderate bullous pemphigoid
NL-OMON46614Phase 2Completed
- Sponsor
- Akari Therapeutics
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in Bullous Pemphigoid (BP), sponsored by Akari Therapeutics. Primary endpoint: Proportion of participants with grade 3, 4, and 5 adverse events related or possibly related to rVA576. Started Jul 2018; status: completed.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NL-OMON46614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46614.